Ginkgo Bioworks Holdings Inc Stock Price, News & Analysis

Ginkgo Bioworks (NYSE: DNA) was awarded a BARDA BioMaP-Consortium project agreement on November 3, 2025 to develop cost-reducing, scalable domestic biomanufacturing innovations for monoclonal antibodies (mAbs) against filoviruses such as Ebola (EBOV) and Sudan virus (SUDV).

The contract value is up to $22.2 million. Ginkgo will lead a partner team (Advanced BioScience Laboratories, Isolere Bio by Donaldson, NeuImmune, and ProteoNic) to integrate technologies across the mAb production process and to produce an anti-filovirus mAb cocktail (1C3 and 1C11) discovered at Emory University. The project is funded in whole or in part by BARDA/ASPR under OT number 75A50123D00003.

Ginkgo Bioworks (NYSE: DNA) announced an extension of its multi-year strategic partnership with Bayer on Oct 31, 2025 to continue joint R&D on agricultural biologicals, including microbial nitrogen fixation. The collaboration, which began in 2017, keeps Bayer's right to commercialize resulting biological products as complements to synthetic fertilizers.

Ginkgo will continue independent partnerships and advance its agricultural biologicals platform, which includes an R&D site in West Sacramento.

Ginkgo Bioworks (NYSE: DNA) will host a third-quarter 2025 results presentation and live Q&A on Thursday, November 6, 2025 beginning at 4:30 p.m. ET. The presentation will review business performance for the quarter ended September 30, 2025.

Webcast details and the replay will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com. Investors can submit questions in advance via X using hashtag #GinkgoResults or by emailing investors@ginkgobioworks.com.

Ginkgo Bioworks (NYSE: DNA) announced a collaboration with STRM.BIO and the University of British Columbia under ARPA-H's EMBODY program to develop in vivo CAR therapies for autoimmune diseases on Oct 23, 2025.

The project, INVITE-ME, will combine STRM.BIO's megakaryocyte-derived extracellular vesicle delivery platform with Ginkgo's RNA construct design, nucleic acid AI, and immune cell engineering to pursue long-lived, tissue-specific CAR expression that could selectively eliminate autoreactive B and T cells without ex vivo manipulation.

Ginkgo Bioworks (NYSE: DNA) has announced new AI initiatives through its Datapoints offering to accelerate biologics drug discovery. The company launched two major programs: a strategic partnership with Apheris to create the Antibody Developability Consortium, and the AbDev AI Competition.

The Consortium aims to tackle biologics development challenges by combining Ginkgo's AI/ML capabilities with Apheris's federated computing infrastructure, allowing secure collaboration while maintaining data ownership. Initial datasets and models for multiple antibody formats are expected in 2026.

The AbDev AI Competition, running until early November with $60,000 in prizes, will establish standards for antibody developability modeling and identify areas needing improvement in the field.

Ginkgo Bioworks (NYSE: DNA) announced the settlement of shareholder derivative actions in the Northern District of California. The settlement includes a $4.125 million payment to be made by Individual Defendants' Insurers to Ginkgo within 30 days after Court judgment. The agreement includes $2.75 million in attorneys' fees and expenses, including $2,000 service awards to plaintiffs.

The settlement requires Ginkgo to terminate a specific contract and implement comprehensive corporate governance reforms for at least three years. The company's Board has determined the settlement terms are fair and in the best interests of Ginkgo and its stockholders. The Settlement Hearing is scheduled for December 18, 2025, where the Court will review the settlement's fairness and approve related fees.

Ginkgo Bioworks (NYSE: DNA) has announced a strategic partnership with Inductive Bio and Tangible Scientific to revolutionize AI-driven drug discovery workflows. The collaboration integrates three key capabilities: Ginkgo Datapoints' ADME profiling, Inductive Bio's chemistry design platform, and Tangible Scientific's compound management system.

The partnership aims to streamline the drug discovery process by combining high-throughput experimental workflows, compound management, and AI models into a unified service. Located in Boston's biopharma hub, the integrated platform offers rapid ADME profiling services including microsomal stability, kinetic solubility, P450 inhibition, and permeability testing, with optional in vitro toxicity assessments.

This collaboration supports the FDA's initiatives for faster development timelines, onshored services, increased AI tool usage, and adoption of non-animal preclinical testing approaches. The services are currently available for pharmaceutical and biotech teams.

Ginkgo Bioworks (NYSE: DNA) has appointed Brian O'Sullivan as Head of Commercial for Ginkgo Automation to accelerate external growth. O'Sullivan, formerly from HighRes Biosolutions, will oversee all revenue-generating functions including sales, business development, and marketing.

The appointment comes as Ginkgo Automation expands from internal R&D support to serving external clients with its RAC (Reconfigurable Automation Cart) hardware, Catalyst scheduling software, and remote monitoring services. O'Sullivan brings extensive experience in commercial leadership, having successfully grown HighRes's operations globally and held senior positions at Agilent Technologies, Velocity11, and Beckman Coulter.

Ginkgo Bioworks (NYSE: DNA) reported Q2 2025 financial results, with total revenue of $50 million, down from $56 million year-over-year. The company's Cell Engineering revenue grew 8% to $39 million, while Biosecurity revenue declined to $10 million. The company reported a GAAP net loss of $60 million, significantly improved from a $217 million loss in the prior year.

Notably, Ginkgo achieved its $250 million annualized cost reduction target three months ahead of schedule through workforce reductions and site consolidation. The company maintains its 2025 outlook of $167-$187 million in total revenue and aims to reach Adjusted EBITDA breakeven by the end of 2026. Ginkgo also expanded its services, launching new automated ADME profiling and cell-free protein synthesis systems.